



Immuron Commences US Investor Roadshow

19 August 2015, Melbourne, Australia: Immuron Limited (ASX:IMC) today wishes to announce that the Company has commenced a US Investor Roadshow where the Company will showcase its technology platform and profile to US investment groups.

This US Roadshow comes off the back of recent market announcements detailing the Company's advances in all product areas of the business, Travelan, NASH, ASH, C-Diff, and now Protectyn.

Travelan:

Immuron announced the execution of a 50,000 minimum annual order supply agreement for the Company's flagship product, Travelan with the major US Travel Clinic supplier, Traveler's Supply Inc.

NASH and ASH Clinical Trials:

The Company's Clinical Trials are progressing well and have been further bolstered by the Company's recent appointments of SVP of Innovation Dr Dan Peres, and Chief Operating and Scientific Officer Dr Jerry Kanellos.

A recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between \$35 - \$40 billion. The high prevalence of Type 2 diabetes and obesity, which lead to NASH and other non-alcoholic fatty liver diseases (NAFLD), boosts the prevalence of NASH and its market growth.

A copy of the US Investor Roadshow Presentation has been attached below.

Contacts:

Dr Roger Aston
Non-Executive Chairman
+61 (0)3 9824 5254

Amanda Loh
Buchan Consulting
+61 (0)3 9866 4722

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers' diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron's main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).


AUGUST 2015

Immuron

ORAL IMMUNOTHERAPY

HEALTH TO CHEW ON

*A Micro biome Company
delivering Oral Immunotherapy
for the treatment and
prevention of disease.*



Forward-looking Statement

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Investment Highlights

Immuron presents the large upside Investor Potential of a biotech company.

It has a unique natural immune-technology platform with GRAS status that significantly reduces the research to product cycle timelines.

Immuron has a revenue-generating product with multiple revenue pathways

Investment Highlights

NASH: Two Phase II studies in progress with
ASH: an increasingly alluring potential upside

Travelan: Revenues growing and positioned to grow
further with successful USA launch

Pipeline: Progressing and Strong

Cap Pofile: Robust

Financials: Debt free, cash in the bank until after
completion of NASH trial

Capital Structure

Market Cap at July 2015 only
AUD\$19.5M

| ASX Code: IMC | Shares | Listed Options | Unlisted Options |
|-------------------------------|--------|----------------|------------------|
| Securities currently on issue | ~75M | ~3M | ~ 6M |

Current Top 20 Shareholders


| Rank | Shareholder Name | Qty Held | % Ownership |
|---|--------------------------------|-------------------|----------------|
| 1 | GRANDLODGE PTY LTD | 6,290,678 | 8.39% |
| 2 | AUTHENTICS AUSTRALIA PTY LTD | 4,999,999 | 6.67% |
| 3 | CHIMAERA CAPITAL LIMITED | 3,635,169 | 4.85% |
| 4 | MR PETER ANASTASIOU & | 2,907,236 | 3.88% |
| 5 | ADVANCE PUBLICITY PTY LTD | 2,100,472 | 2.80% |
| 6 | FIFTY-FIFTH LEPRECHAUN PTY LTD | 2,035,371 | 2.72% |
| 7 | MRS JACLYN STOJANOVSKI & | 1,974,807 | 2.63% |
| 8 | INSYNC INVESTMENTS PTY LTD | 1,534,432 | 2.05% |
| 9 | HADASIT MEDICAL RESEARCH | 1,479,102 | 1.97% |
| 10 | MR DAVID ANTHONY PLUSH & | 1,334,075 | 1.78% |
| 11 | MR KENNETH BIDDICK & | 1,249,999 | 1.67% |
| 12 | G & N LORD SUPERANNUATION PTY | 1,237,994 | 1.65% |
| 13 | MR DALE ANTHONY REED | 1,200,000 | 1.60% |
| 14 | JOJO ENTERPRISES PTY LTD | 918,898 | 1.23% |
| 15 | MR IAN DAVID PATTISON & | 657,674 | 0.88% |
| 16 | CAPITAL CONCERNS PTY LIMITED | 654,716 | 0.87% |
| 17 | SOMNUS PTY LTD | 625,000 | 0.83% |
| 18 | MR HAMISH SALMON & | 575,000 | 0.77% |
| 19 | T E & J PASIAS PL | 560,000 | 0.75% |
| 20 | ADVANCE CLINICAL SYSTEMS | 546,874 | 0.73% |
| TOTAL OF TOP 20 SHAREHOLDERS | | 36,517,496 | 48.71% |
| Balance of Remaining Shareholders (1,161 Holders) | | 38,446,736 | 51.29% |
| TOTAL SHARES ON ISSUE (1,181 Holders) | | 74,964,232 | 100.00% |

What do we do?

Targeting the human immune system with natural antibodies derived from bovine to address diseases of the gut and liver.

Why?

Acute and chronic infections in the gut have a major impact in human health, causing dis biosis and many metabolic diseases.



Unique Platform Technology


- ✓ Attractive risk-reward ratio – biotech upside with reduced risk profile

| Immuron's Platform Products | Other Products |
|---|--|
| ✓ Natural product | ✗ Synthetic product |
| ✓ High safety profile | ✗ Side effects occur |
| <ul style="list-style-type: none"> ✓ Not a binary outcome. ✓ If clinical end points not attained, there may still be a product that generates revenue | ✗ Binary outcome: clinical trial failure means there is no product |
| ✓ Low Cost | ✗ Antibodies typically very expensive to make |

Pathway with reduced risk

Traditional model

Immuron's De-risked Platform





immuron

2.
TRAVELAN®
Stop it before it starts

Travelan[®] - a Unique Preventative Product



The only therapy that prevents travellers' diarrhoea by up to 90%*

Without Travelan[®]: Bacteria attach to gut wall and infect



With Travelan[®]: Bacteria neutralized by Travelan[®] antibodies



OVERVIEW

TRAVELAN

NASH

PIPELINE

SUMMARY

Immuron

Travelan®

<http://www.travelan.com.au>

HOME | WHAT IS TD | HOW DOES TRAVELAN WORK | HOW TO AVOID TD | BUY ONLINE | REAL STORIES | CONTACT US

Travelan® Stop it before it starts Don't let DIARRHOEA ruin your trip

Travelan v2 splitscreen

Travelan Reduces the risk of Travellers' Diarrhoea

YOU NEED PREVENTION NOT RELIEF!

CLINICALLY PROVEN OVER 90% PROTECTION

BUY NOW!

What is Travelan?

Travelan is a natural product, specifically designed to reduce the risk of infection by Enterotoxigenic *E. coli* (ETEC), the most common cause of Travellers' Diarrhoea. **More information**

What is Travellers' Diarrhoea?

Travellers' Diarrhoea also known as Bali Belly, Delhi Belly, Montezuma's Revenge, Tourist Trot, Rangoon Runs or just TD, is a result of ingesting contaminated food and/or water. It is the most common illness affecting international travellers. **More information**

Where should I take Travelan?

Any country other than that where you normally live can be a potential infection threat.

Some areas are a higher risk to travellers such as South and Central America, Africa, the Middle East, Asia and the Indian sub-continent. Areas with poor sanitation – in particular regarding water supply are especially high-risk.

For more travel information visit smartraveller.gov.au

Travel Checklist

- ✓ Passport
- ✓ Tickets
- ✓ Wallet
- ✓ Travelan

Travelan Stop it before it starts



Traveller's diarrhoea global market estimate: US\$600M - 1.2B



All-natural product; clinically proven with very high safety profile



Available over-the-counter



Strong brand loyalty

11

Immuron Investor Presentation

July 2015

Travelan[®]

Growing Australian brand



Travelan[®]

Successfully Launched in the USA



Sales & marketing directly to Travel Clinics and specialist sub-distributors



Online sales

**** Note:** first non-exclusive distribution contract signed for 50,000 units in July 2015 with major Traveller's Supply company at full margin.

Travelan®

———— Status in Nov 2013

————→ Progress in 2015




* Regulatory application preceding partnering engagement



Immuron

3.
NASH/ASH
(INFLAMED
FATTY LIVER)

What is NASH? – a spectrum of conditions



OVERVIEW

TRAVELAN


NASH/ASH

PIPELINE

SUMMARY

Immuron

What is NASH? – Some numbers



OVERVIEW

TRAVELAN

NASH/ASH

PIPELINE

SUMMARY

Immuron

NASH – How Big is the Opportunity?

How Big is the Opportunity?



= Estimated \$40B Market in 2025

NASH - The Next Big Global Epidemic in 10 Years?

Deutsche Bank, Markets Research, 14 July 2014

OVERVIEW

TRAVELAN

NASH/ASH

PIPELINE

SUMMARY

Immuron

There is also ASH: alcoholic steatohepatitis



My Doctor said "Only one glass of alcohol a day"

....I can live with that.

IMM-124E chosen by NIH from 27 candidates for a phase II study in ASH. Currently recruiting.

OVERVIEW

TRAVELAN

NASH/ASH

PIPELINE

SUMMARY

Immuron

Current Treatments Available for NASH?



None

OVERVIEW

TRAVELAN

NASH/ASH

PIPELINE


SUMMARY

Immuron

Immuron's Solution for ASH and NASH

IMM-124E treats the liver and improves insulin resistance, liver function and reduces high cholesterol, by reducing inflammation and fibrosis.

IMM-124E operates only in the gut and does not enter bloodstream



2 Phase II trials started and recruiting

NASH- IMMURON FUNDED

Phase II trial has begun:

- Over 20 world class sites participating
- First 30 patients randomised or dosed


ASH- NIH FUNDED

Phase II trial has begun:

- Currently Recruiting
- Patients randomised and dosed

NIH funded,
selected as 1 of 3 (from a possible 27)
treatments to be funded by the NIH

NASH Sites - Australia



NASH Sites – United States



The Competitive Landscape

Bile Acid

Shire - LUM-002

Intercept - Obeticholic acid, modified bile acid

Galmed - Aramchol, Conjugate of Fatty acid and Fatty bile acid

Anti-fibrotic

Gilead - Simtuzumab, anti-fibrotic

Galectin - galectin proteins

Anti-Inflammatory + (anti-inflammatory, anti-diabetic, cholesterol control, FFA)

Immuron - Hyperimmune colostrum enriched with Anti-LPS Abs

Conatus - Emricassan, caspase protease inhibitor

Genfit - Peroxisome proliferator - activated receptor alpha

NASH is a Spectrum of conditions:
Room for many therapies

✓ IMM-124E is safe and may be best in class

The Immuron logo is located in the top right corner of the slide. It consists of the word "Immuron" in a blue, sans-serif font, with a stylized circular icon to the right of the letter "n". The background of the slide is a blue gradient with a semi-transparent anatomical illustration of a human torso, showing internal organs like the lungs, heart, and intestines. The intestines are highlighted in a warm, glowing orange and red color.

Immuron

4.
ROBUST
PIPELINE

The Immuron Pipeline

Indication Research Pre-clinical Phase I Phase II Phase III Market

Traveller's
Diarrhea



NASH
(IMM-124E)



ASH
(IMM-124E)



* Trial funded by NIH

Clostridium
difficile
infection



Other Projects:




- diabetes
- Colitis/Crohn's Disease
- Fibrosis

In the pipeline

- IMM-529 as therapy for infections due to overuse of antibiotics
- Clostridium difficile (C.diff): a gut-borne bacteria
 - superbug
 - more than US\$3.2 billion in health care costs each year in the United States
- IMM-529 under collaboration with Monash University
- Exceptional pre-clinical results to date:
 - 80% prevention
 - 100% cure in mouse model.

US Hospitalisations Skyrocket Annually due to C.diff



Source: Agency for Healthcare Research and Quality

28

Immuron
Investor
Presentation

July 2015

Comparative Values- Nasdaq Peers

* Immuron is significantly undervalued relative to peers listed on NASDAQ who are currently undertaking a Phase II study in NASH

Average Value for these Companies is over \$100 Million

* Immuron is significantly undervalued relative to its peers listed on NASDAQ that currently have a C-Diff program in place.

Average Value of these companies is over \$200 Million, although several are in Phase II or Phase III clinical trials.

At \$20 Million Immuron represents a strong Value case with Two phase II studies, a C- Diff program, Travelan sales and a strong pipeline and safe platform.

5. SUMMARY

Looking Forward 2015-16

| | |
|-------------------------|---|
| Travelan | <ol style="list-style-type: none"> 1. Continue to increase Australian Travelan revenue 2. Increase Canadian Travelan revenue 3. Outstanding early Launch in the US 4. Continue to progress elsewhere overseas |
| Another Products | <ol style="list-style-type: none"> 5. Launch anti Lps products in Australia |
| NASH | <ol style="list-style-type: none"> 6. Recruit patients and manage recruitment rate 7. Increase profile amongst KOLs, prospective licensees and investment community |
| Other | <ol style="list-style-type: none"> 8. Continue to progress C difficile project 9. Diabetes 10. Colitis and Crohn's |

The Board and Management

Dr Roger Aston
Chairman

Roger has more than 20 years of experience in the pharmaceutical and biotech industries. He was the Founding CEO Chief Executive Officer and a Director of Mayne Pharma Group Limited.

Daniel Pollock
Non-Executive Director

Daniel is an internationally experienced lawyer admitted in both Scotland and Australia, with significant commercial expertise in new market entries into overseas markets, distribution agreements and start ups.

Stephen Anastasiou
Non-Executive Director

Stephen has extensive experience in general management, marketing and strategic planning in the healthcare industry, formerly with KPMG.

Peter Anastasiou
Director

Peter Anastasiou was the founder of major shareholder Grandlodge and has had 20 years of successful investment across many sectors. He started his first Bio Tech at age 23, and has a strong philanthropic Portfolio.

Dan Peres, MD
Senior VP of Innovation

Dan had been leading Medical Device and Pharma companies in their clinical stage since 2008. a Physician in origin has years of experience in management and medical development .

Neta Tobis
Clinical Director

With over 7 years' experience of international trial management for small to large pharma and medical device companies as well as working within large CROs (PPD)

Dr. Yaron Ilan
Medical Officer

Dr. Yaron Ilan, MD, is a Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles.

Dr. Jerry Kanellos
Chief Scientific Officer

Jerry has had over 20 years experience in Pharma and Biotech and has a wealth of knowledge and experience in Regulatory, R&D and QC.

Nicky Konstantopolous
Development Manager

Nicky is an experienced scientist with expertise in insulin action and metabolic conditions. She has held postdoctoral roles with the Joslin Diabetes Centre at Harvard Medical School (Boston) and CSIRO (Parkville, Melbourne).

Reza Moussakhani
Manufacturing Quality Director

A professional Operations manager with extensive experience in implementation of project / quality and process improvements including with Hospira and Sigma Pharmaceuticals.

Immuron

THANK YOU

